A late clinical trial demo the Pfizer - BioNTech COVID-19 vaccinum elicits " 100 percentage efficacy and full-bodied antibody reply " in teen from 12 to 15 years old , according to an promulgation from the pharmaceutical company .
The declaration was made on Wednesday viaa company mechanical press releaseand the findings are not to be issue or peer - reviewed yet . Nevertheless , if the results hold strong , they could open up the door to extending inoculation to this age chemical group and younger .
The results number from a Phase 3 visitation in 2,260 stripling age 12 to 15 in the US . During the clinical trial , 18 masses in the placebo group originate COVID-19 , while no one in the immunized grouping catch the infection . The descent test also revealed promising results , showing the vaccinum sparks a strong resistant response , even more so than those recorded earlier in people aged 16 to 25 years one-time .
Pfizer also said that they ’ve just dosed the first participants in a clinical survey assess their COVID-19 vaccinum on three young age groups : child age 5 to 11 years , 2 to 5 years , and 6 months to 2 year . The results will be released in due course .
So far , there has been a throng of clinical trial testing the unlike COVID-19 vaccinum in adults - most of which havebeen very promising . However , certain chemical group of people ( such as adolescent ) were not included in the initial round of clinical trials , meaning there was not enough hard datum to guide vaccine decision . Now , a cluster of field of study is broadening the datum available . For case , a study give up last week that find out the Pfizer / BioNTech and Moderna COVID-19 vaccines are dependable andhighly effective during pregnancy
Expertscommenting on the newssaid the announcement holds a wad of hope , but the findings need further confirmation since they were only revealed in a short jam release , not a match - critique study .
“ As with most such press releases , details are panty , making it hard to point out confidently on the validity of the claims made . It would be very helpful to see the full detail in one or more match - refresh report , ” said Dr Peter English , Retired advisor in Communicable Disease Control and past Chair of the BMA Public Health Medicine Committee .
“ When the full , peer - reexamine newspaper come along – or when regulators have the data directly from the party – it will open up the mode to poke out vaccination to this years chemical group ( and likely to the vernal age grouping referred to in the press release ) . It will be significant to do this to achieve herd immunity , ” added Dr English .
